[{"id":"853b2c7a-ae04-4c10-89b6-0e2751505bec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04812652","created_at":"2024-05-04T04:26:52.545Z","updated_at":"2024-07-02T16:35:06.634Z","phase":"","brief_title":"Digitally Distributed Yoga for Women Treated for Breast Cancer","source_id_and_acronym":"NCT04812652","lead_sponsor":"Region Örebro County","biomarkers":" TNFA • CXCL8 • IGF1 • IGF2 • IL1B • LEP","pipe":"","alterations":" ","tags":["TNFA • CXCL8 • IGF1 • IGF2 • IL1B • LEP"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 229","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-05-01"},{"id":"bb9997f0-453a-4083-9fab-d8017d881de5","acronym":"1R01CA172444-01A1","url":"https://clinicaltrials.gov/study/NCT02028221","created_at":"2021-01-18T09:17:16.755Z","updated_at":"2024-07-02T16:35:44.648Z","phase":"Phase 2","brief_title":"Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk","source_id_and_acronym":"NCT02028221 - 1R01CA172444-01A1","lead_sponsor":"University of Arizona","biomarkers":" IGF1 • IGF2 • IGFBP3 • LEP","pipe":"","alterations":" ","tags":["IGF1 • IGF2 • IGFBP3 • LEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Completed","enrollment":" Enrollment 151","initiation":"Initiation: 03/07/2014","start_date":" 03/07/2014","primary_txt":" Primary completion: 11/30/2018","primary_completion_date":" 11/30/2018","study_txt":" Completion: 06/14/2022","study_completion_date":" 06/14/2022","last_update_posted":"2023-06-27"},{"id":"81495bd9-2ae2-4b7a-bf03-c5d38eafb6ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT04266353","created_at":"2021-01-18T20:43:49.572Z","updated_at":"2024-07-02T16:35:48.613Z","phase":"","brief_title":"Effect of Resveratrol on Serum IGF2 Among African American Women","source_id_and_acronym":"NCT04266353","lead_sponsor":"Loma Linda University","biomarkers":" IGF2 • IGFBP3","pipe":"","alterations":" ","tags":["IGF2 • IGFBP3"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/24/2019","start_date":" 04/24/2019","primary_txt":" Primary completion: 08/22/2022","primary_completion_date":" 08/22/2022","study_txt":" Completion: 08/22/2022","study_completion_date":" 08/22/2022","last_update_posted":"2023-05-09"},{"id":"25b49b5c-1205-49a0-873e-9be6de80eb2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03576963","created_at":"2021-01-18T14:26:35.700Z","updated_at":"2025-02-25T14:27:13.292Z","phase":"Phase 1/2","brief_title":"Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03576963","lead_sponsor":"University of Southern California","biomarkers":" PD-L1 • IGF2 • SOCS1 • RUNX3 • NEUROG1","pipe":" | ","alterations":" RAS wild-type","tags":["PD-L1 • IGF2 • SOCS1 • RUNX3 • NEUROG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • guadecitabine (SGI-110)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/30/2020","start_date":" 01/30/2020","primary_txt":" Primary completion: 01/30/2022","primary_completion_date":" 01/30/2022","study_txt":" Completion: 01/30/2023","study_completion_date":" 01/30/2023","last_update_posted":"2021-04-05"},{"id":"c7430dc9-01ea-42e0-b7c3-86cf71195b7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01446159","created_at":"2021-01-18T05:59:58.146Z","updated_at":"2024-07-02T16:36:44.570Z","phase":"Phase 1b/2","brief_title":"Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer","source_id_and_acronym":"NCT01446159","lead_sponsor":"MedImmune LLC","biomarkers":" HER-2 • IGF2","pipe":"","alterations":" ","tags":["HER-2 • IGF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • dusigitumab (MEDI-573)"],"overall_status":"Completed","enrollment":" Enrollment 188","initiation":"Initiation: 06/13/2011","start_date":" 06/13/2011","primary_txt":" Primary completion: 06/28/2019","primary_completion_date":" 06/28/2019","study_txt":" Completion: 06/28/2019","study_completion_date":" 06/28/2019","last_update_posted":"2020-06-02"},{"id":"d1f2bba3-a066-4ab2-ade4-ee5dabc41dd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00781911","created_at":"2021-01-18T02:57:16.581Z","updated_at":"2024-07-02T16:36:55.434Z","phase":"Phase 2","brief_title":"A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer","source_id_and_acronym":"NCT00781911","lead_sponsor":"Eli Lilly and Company","biomarkers":" IGF1 • IGF2","pipe":"","alterations":" ","tags":["IGF1 • IGF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cixutumumab (IMC A12) • octreotide acetate solution for injection"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 07/01/2011","primary_completion_date":" 07/01/2011","study_txt":" Completion: 05/01/2016","study_completion_date":" 05/01/2016","last_update_posted":"2019-09-20"},{"id":"357dc3dd-3511-4e3e-92dc-2dae662ea8ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT00816361","created_at":"2021-01-18T03:06:08.124Z","updated_at":"2024-07-02T16:37:02.295Z","phase":"Phase 1","brief_title":"A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT00816361","lead_sponsor":"MedImmune LLC","biomarkers":" IGF1 • IGF2","pipe":"","alterations":" ","tags":["IGF1 • IGF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dusigitumab (MEDI-573)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 03/09/2009","start_date":" 03/09/2009","primary_txt":" Primary completion: 09/11/2012","primary_completion_date":" 09/11/2012","study_txt":" Completion: 09/11/2012","study_completion_date":" 09/11/2012","last_update_posted":"2019-03-04"},{"id":"b02bbce8-c9f2-468f-acdc-98a877b32fb5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01762241","created_at":"2021-01-18T07:44:49.719Z","updated_at":"2024-07-02T16:37:02.330Z","phase":"","brief_title":"Xbox Kinect Training in Men With Prostate Cancer","source_id_and_acronym":"NCT01762241","lead_sponsor":"Hospitalsenheden Vest","biomarkers":" IGF1 • IGF2 • IGFBP1","pipe":"","alterations":" ","tags":["IGF1 • IGF2 • IGFBP1"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2019-03-01"},{"id":"4dde3a27-c71b-4b5b-b044-b458ed2a0688","acronym":"","url":"https://clinicaltrials.gov/study/NCT01949519","created_at":"2021-01-18T08:50:19.547Z","updated_at":"2024-07-02T16:37:14.931Z","phase":"Phase 1","brief_title":"Docetaxel and Lycopene in Metastatic Prostate Cancer","source_id_and_acronym":"NCT01949519","lead_sponsor":"Medical University of South Carolina","biomarkers":" IL6 • IGF1 • IGF2 • IGFBP3","pipe":"","alterations":" ","tags":["IL6 • IGF1 • IGF2 • IGFBP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 07/12/2017","study_completion_date":" 07/12/2017","last_update_posted":"2018-01-11"},{"id":"87444fb5-f6d8-4c09-8d8d-800aa22aa475","acronym":"","url":"https://clinicaltrials.gov/study/NCT03026361","created_at":"2021-01-18T14:53:43.602Z","updated_at":"2024-07-02T16:37:26.376Z","phase":"","brief_title":"Molecular Mechanisms of the Development of Precancerous and Cancerous Lesions of the Oral Cavity","source_id_and_acronym":"NCT03026361","lead_sponsor":"University of Zagreb","biomarkers":" IGF2","pipe":"","alterations":" ","tags":["IGF2"],"overall_status":"Completed","enrollment":" Enrollment 71","initiation":"Initiation: 01/01/2010","start_date":" 01/01/2010","primary_txt":" Primary completion: 12/01/2014","primary_completion_date":" 12/01/2014","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2017-01-20"},{"id":"da723a82-8bbb-4bf3-a66f-556efc588883","acronym":"","url":"https://clinicaltrials.gov/study/NCT01325311","created_at":"2022-11-19T23:56:43.512Z","updated_at":"2024-07-02T16:37:30.023Z","phase":"Phase 2a","brief_title":"Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer","source_id_and_acronym":"NCT01325311","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IGF2","pipe":"","alterations":" ","tags":["IGF2"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2016-08-03"}]